Articles

St. Francis resumes work on $265M project

With its financial performance exceeding expectations, St. Francis Hospital & Health Centers will resume construction on a $265 million, 221-bed patient tower at its Indianapolis campus, the hospital system announced Thursday.

Read More

Hospitals, doctors finally integrating patient care

The stitching together of doctors and hospitals—two groups that historically have kept each other at arm’s length—is
a trend picking up speed locally and nationally and could accelerate even further if Congress passes health care reform.

Read More

Clarian CEO pines anew for public insurance option

Most business groups cheered when Sen. Max Baucus, D-Mont., introduced a health reform bill with no so-called public option,
a controversial government-run insurance plan for working adults. But there’s a big group that would like
to see it back on the table—hospitals.

Read More

Lilly agrees to settle more state Zyprexa suits

Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.

Read More

Lilly sells constipation drug to Adolor

Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.

Read More

Lilly: Alimta improves lung-cancer survival time

Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.

Read More

A beachhead in Warsaw

The launch of the orthopedics not-for-profit OrthoWorx is quite an accomplishment in Warsaw, where some of the world’s
biggest companies fight tooth-and-nail.

Read More

UPDATE: Pipeline challenges force Lilly restructuring moves

Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.

Read More